Murlentamab

Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) . Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming[1].

Product Specifications

CAS Number

[2058047-65-5]

Product Name Alternative

3C23K; GM102

UNSPSC

12352203

Target

TGF-β Receptor

Type

Inhibitory Antibodies

Related Pathways

TGF-beta/Smad

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/murlentamab.html

Purity

95.00

Solubility

10 mM in DMSO

Smiles

[Murlentamab]

Molecular Weight

(144.56 kDa)

References & Citations

[1]Prat M, et al. Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation. Cancers (Basel) . 2021 Apr 13;13 (8) :1845. |[2]Barret JM, et al. The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer. Biology (Basel) . 2021 Apr 7;10 (4) :305.